A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Oh-oh-oh Ozempic. Originally marketed for treating Type 2 diabetes, Ozempic—perhaps the most popular of the injectable medications called semaglutide that was FDA-approved in 2017—has become ...

Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report published in the BMC Nephrology. Hyperkalemic Periodic Paralysis (HyperPP) is ...

At the 2-year, 3-year, and 4-year time points from the index date, those taking semaglutide had an increased risk for nonarteritic anterior ischemic optic neuropathy. HealthDay News — For patients ...

New Delhi: Considering the bioequivalence (BE) study report of the antidiabetic drug Semaglutide solution for injection (synthetic origin) 0.25mg /0.5ml, 0.5 mg /0.5ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml and ...

Ozempic (semaglutide) is prescribed to treat type 2 diabetes mellitus. It works by stimulating insulin to manage blood sugar levels. It also slows down digestion and provides signals to the brain that ...